Freeline Therapeutics Stock Performance
NASDAQ:FRLN opened at $5.76 on Tuesday. Freeline Therapeutics has a 52-week low of $2.11 and a 52-week high of $10.20. The stock has a fifty day moving average of $4.43 and a 200 day moving average of $3.77. The firm has a market capitalization of $25.00 million, a price-to-earnings ratio of -0.69 and a beta of 0.39.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on FRLN. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Freeline Therapeutics in a research report on Thursday, August 17th. Wedbush lowered shares of Freeline Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $8.00 to $5.00 in a research report on Wednesday, October 18th.
Hedge Funds Weigh In On Freeline Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp purchased a new position in shares of Freeline Therapeutics during the 2nd quarter valued at about $40,000. Federated Hermes Inc. lifted its holdings in shares of Freeline Therapeutics by 50.0% in the 1st quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $67,000 after acquiring an additional 20,000 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Freeline Therapeutics in the 1st quarter worth approximately $30,000. Renaissance Technologies LLC boosted its stake in shares of Freeline Therapeutics by 17.4% in the 1st quarter. Renaissance Technologies LLC now owns 230,600 shares of the company’s stock valued at $105,000 after purchasing an additional 34,210 shares in the last quarter. Finally, UBS Group AG bought a new position in shares of Freeline Therapeutics during the 1st quarter valued at $565,000. 46.26% of the stock is currently owned by hedge funds and other institutional investors.
About Freeline Therapeutics
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease.
- Five stocks we like better than Freeline Therapeutics
- What Does a Stock Split Mean?
- Safeguard your portfolio with these three bargain stocks
- Canadian Penny Stocks: Can They Make You Rich?
- Membership clubs gain leverage for the consumer rebound
- How to Invest in Casino Stocks
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.